US drug manufacturer Vertex has reached an agreement with Equity Pharmaceuticals to import and distribute its cystic fibrosis treatment Trikafta in SA, but the drug’s high price tag means it is likely to remain out of reach for many eligible patients.
Only one medical scheme — Discovery Health Medical Scheme (DHMS) — now offers a benefit with cover for this class of drug, known as Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, and even these patients may face co-payments for Trikafta...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.